Distinct clinical outcomes of non-small cell lung cancer patients with Epidermal Growth Factor Receptor (EGFR) mutations treated with EGFR tyrosine kinase inhibitors: Non-responders versus responders

Shih Hsin Hsiao, H. Eugene Liu, Hsin Lun Lee, Chii Lan Lin, Wei Yu Chen, Zhung Han Wu, Sey En Lin, Ling Ling Chiang, Chi Li Chung

Research output: Contribution to journalArticle

8 Citations (Scopus)


Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been associated with favorable progression free survival (PFS) in patients with non-small cell lung cancers (NSCLC) harboring EGFR mutations. However, a subset of this population doesn't respond to EGFR-TKI treatment. Therefore, the present study aimed to elucidate survival outcome in NSCLC EGFR-mutant patients who were treated with EGFR TKIs. Methods: Among the 580 consecutive NSCLC patients who were treated at our facility between 2008 and 2012, a total of 124 treatment-naïve, advanced NSCLC, EGFR-mutant patients treated with EGFR TKIs were identified and grouped into nonresponders and responders for analyses. Results: Of 124 patients, 104 (84%) responded to treatment, and 20 (16%) did not; and the overall median PFS was 9.0 months. Notably, the PFS, overall survival (OS) and survival rates were significantly unfavorable in non-responders (1.8 vs. 10.3 months, hazard ratio (HR) = 29.2, 95% confidence interval (CI), 13.48-63.26, P

Original languageEnglish
Article numbere83266
JournalPLoS One
Issue number12
Publication statusPublished - Dec 23 2013


ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this